NightstaRx Ltd, a one-year old gene therapy company, has received £5 million in new venture finance to expedite the development of a treatment for choroideremia, an inherited cause of progressive blindness. This brings total funding for the company to £17 million.
Content matching 'gene therapy'
Cell and Gene Therapy Catapult enters into partnership with Forum for Innovative Regenerative Medicine
Overcoming the obstacles to a commercially successful cell or gene therapy: an interview with Dr Nafees Malik
Latest news & views, Spotlight on gene therapy, Spotlight on immunotherapy, Spotlight on commercialization and translation, Spotlight on cell therapy regulation, Cell therapy, Manufacturing & scale-up, Ethics & policy, Industry developments
Keeping patients safe from unproven cell therapies: an interview with the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies
Editor’s highlights: Opportunities and Challenges in Translating Cell and Gene Therapy Products